Kenneth S Kendler1, Henrik Ohlsson1, Jan Sundquist1, Kristina Sundquist1. 1. The Virginia Institute for Psychiatric and Behavioral Genetics and the Department of Psychiatry, Virginia Commonwealth University, Richmond (Kendler); the Center for Primary Health Care Research, Lund University, Malmö, Sweden (Ohlsson, J. Sundquist, K. Sundquist); the Department of Family Medicine and Community Health, Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York (J. Sundquist, K. Sundquist); the Center for Community-Based Health Care Research and Education, Department of Functional Pathology, School of Medicine, Shimane University, Japan (J. Sundquist, K. Sundquist).
Abstract
OBJECTIVE: The objective of this study was to clarify the etiology of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample. METHODS: Individuals with a registration of substance-induced psychotic disorder between 1997 and 2015 in national medical registries (N=7,606) were followed up for a mean of 84 months. Data from medical, criminal, and pharmacy registries on first-degree through third-degree relatives were used to calculate familial risk scores for nonaffective psychosis, drug abuse, and alcohol use disorder. RESULTS: Individuals with substance-induced psychotic disorder had large elevations in standardized familial risk scores for drug abuse (+1.09, 95% CI=1.02, 1.15) and alcohol use disorder (+0.98, 95% CI=0.93, 1.03) and modest elevations for nonaffective psychosis (+0.35, 95% CI=0.30, 0.41). The cumulative risk for progression to schizophrenia was 11.3%; it was lowest for alcohol-induced and highest for cannabis-induced psychotic disorder, and it was predicted by early age at diagnosis of substance-induced psychotic disorder, male sex, and further registrations for episodes of drug abuse, alcohol use disorder, and substance-induced psychotic disorder. A risk prediction model found that 47% of individuals who converted to schizophrenia were in the upper 20% of risk. Familial risk scores for drug abuse and alcohol use disorder did not significantly discriminate those who converted to schizophrenia from those who did not, while familial risk score for nonaffective psychosis did (0.67, 95% CI=0.40, 0.95, versus 0.33, 95% CI=0.28, 0.39). Familial risk scores for nonaffective psychosis were indistinguishable between individuals with schizophrenia with and without prior substance-induced psychosis. Assignment of early retirement by the Swedish Social Insurance Agency strongly discriminated between individuals with substance-induced psychotic disorder with and without later schizophrenia. CONCLUSIONS: Substance-induced psychotic disorder appears to result from substantial drug exposure in individuals at high familial risk for substance abuse and moderately elevated familial risk for psychosis. Familial risk for psychosis, but not substance abuse, predicts progression from substance-induced psychosis to schizophrenia. Schizophrenia following substance-induced psychosis is likely a drug-precipitated disorder in highly vulnerable individuals, not a syndrome predominantly caused by drug exposure.
OBJECTIVE: The objective of this study was to clarify the etiology of substance-induced psychotic disorder and its progression to schizophrenia in a Swedish national sample. METHODS: Individuals with a registration of substance-induced psychotic disorder between 1997 and 2015 in national medical registries (N=7,606) were followed up for a mean of 84 months. Data from medical, criminal, and pharmacy registries on first-degree through third-degree relatives were used to calculate familial risk scores for nonaffective psychosis, drug abuse, and alcohol use disorder. RESULTS: Individuals with substance-induced psychotic disorder had large elevations in standardized familial risk scores for drug abuse (+1.09, 95% CI=1.02, 1.15) and alcohol use disorder (+0.98, 95% CI=0.93, 1.03) and modest elevations for nonaffective psychosis (+0.35, 95% CI=0.30, 0.41). The cumulative risk for progression to schizophrenia was 11.3%; it was lowest for alcohol-induced and highest for cannabis-induced psychotic disorder, and it was predicted by early age at diagnosis of substance-induced psychotic disorder, male sex, and further registrations for episodes of drug abuse, alcohol use disorder, and substance-induced psychotic disorder. A risk prediction model found that 47% of individuals who converted to schizophrenia were in the upper 20% of risk. Familial risk scores for drug abuse and alcohol use disorder did not significantly discriminate those who converted to schizophrenia from those who did not, while familial risk score for nonaffective psychosis did (0.67, 95% CI=0.40, 0.95, versus 0.33, 95% CI=0.28, 0.39). Familial risk scores for nonaffective psychosis were indistinguishable between individuals with schizophrenia with and without prior substance-induced psychosis. Assignment of early retirement by the Swedish Social Insurance Agency strongly discriminated between individuals with substance-induced psychotic disorder with and without later schizophrenia. CONCLUSIONS:Substance-induced psychotic disorder appears to result from substantial drug exposure in individuals at high familial risk for substance abuse and moderately elevated familial risk for psychosis. Familial risk for psychosis, but not substance abuse, predicts progression from substance-induced psychosis to schizophrenia. Schizophrenia following substance-induced psychosis is likely a drug-precipitated disorder in highly vulnerable individuals, not a syndrome predominantly caused by drug exposure.
Authors: Paul Lichtenstein; Camilla Björk; Christina M Hultman; Edward Scolnick; Pamela Sklar; Patrick F Sullivan Journal: Psychol Med Date: 2006-07-25 Impact factor: 7.723
Authors: Kenneth S Kendler; Kristina Sundquist; Henrik Ohlsson; Karolina Palmér; Hermine Maes; Marilyn A Winkleby; Jan Sundquist Journal: Arch Gen Psychiatry Date: 2012-07
Authors: Birgit Ekholm; Andreas Ekholm; Rolf Adolfsson; Maria Vares; Urban Osby; Göran C Sedvall; Erik G Jönsson Journal: Nord J Psychiatry Date: 2005 Impact factor: 2.202
Authors: Chih-Ken Chen; Shih-Ku Lin; Pak C Sham; David Ball; El-Wui Loh; Robin M Murray Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2005-07-05 Impact factor: 3.568
Authors: Paul Lichtenstein; Benjamin H Yip; Camilla Björk; Yudi Pawitan; Tyrone D Cannon; Patrick F Sullivan; Christina M Hultman Journal: Lancet Date: 2009-01-17 Impact factor: 79.321
Authors: Krishna T Patel; Michael C Stevens; Amanda Dunlap; Alana Gallagher; Stephanie S O'Malley; Kelly DeMartini; Marc N Potenza; John H Krystal; Godfrey D Pearlson Journal: Neuropsychopharmacology Date: 2021-09-02 Impact factor: 8.294
Authors: Rebecca McKetin; Janni Leung; Emily Stockings; Yan Huo; James Foulds; Julia M Lappin; Craig Cumming; Shalini Arunogiri; Jesse T Young; Grant Sara; Michael Farrell; Louisa Degenhardt Journal: EClinicalMedicine Date: 2019-10-17